Shares Magazine
Jump to:
Oncimmune Holdings Fundamentals
| Company Name | Oncimmune Holdings | Last Updated | 17 Apr 2019 |
|---|---|---|---|
| Industry | Health Care | Sector | Pharmaceuticals & Biotechnology |
| Shares in Issue (m) | 63.25 | Market Cap (£m) | 62.62 |
| PE Ratio | -8.68 | Div per Share (p) | 0.00 |
| Div Yield | 0.00 | Div Cover | 0.00 |
| EPS | -11.41 | EPS Growth (%) | -15.96 |
| PEG | 0.54 | DPS Growth (%) | n/a |
| Debt Ratio | 0.00 | Debt Equity Ratio | 0.00 |
| Net Gearing | -83.99 | Gross Gearing | 5.89 |
| Asset Equity Ratio | 1.06 | Cash Equity Ratio | 95.51 |
| Quick Ratio | 15.60 | Current Ratio | 15.95 |
| Price To Book Value | 4.62 | ROCE | -46.76 |
Oncimmune Holdings Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Oncimmune Holdings Company Financials
| Assets (£m) | 2018 | 2017 | 2016 |
|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 |
| Intangible Assets | 1 | 1 | 0 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | 1 | 1 | 0 |
| Stocks | 0 | 0 | 0 |
| Debtors | 0 | 0 | 0 |
| Cash & Equivalents | 13 | 5 | 10 |
| Other Assets | 0 | 0 | 0 |
| Total Assets | 14 | 6 | 11 |
| Liabilities (£m) | 2018 | 2017 | 2016 |
|---|---|---|---|
| Creditors within 1 year | 1 | 1 | 1 |
| Creditors after 1 year | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | 1 | 1 | 1 |
| Net assets | 14 | 5 | 10 |
| Equity (£m) | 2018 | 2017 | 2016 |
|---|---|---|---|
| Called up share capital | 1 | 1 | 1 |
| Share Premium | 31 | 16 | 16 |
| Profit / Loss | -6 | -5 | -9 |
| Other Equity | 31 | 31 | 31 |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | 14 | 5 | 10 |
| Ratios | 2018 | 2017 | 2016 |
|---|---|---|---|
| Debt Ratio | 0.00 | 0.00 | 3.90 |
| Debt-to-Equity | 0.00 | 0.00 | 0.27 |
| Net Gearing | -83.99 | -57.31 | -77.80 |
| Gross Gearing | 5.89 | 21.90 | 13.18 |
| Assets / Equity | 1.06 | 1.28 | 1.15 |
| Cash / Equity | 95.51 | 101.42 | 104.79 |
| EPS | -11.41 | -9.84 | -23.54 |
| Cash Flow (£m) | 2018 | 2017 | 2016 |
|---|---|---|---|
| Cash from operating activities | -6 | -4 | -3 |
| Cashflow before financing | -6 | -5 | -3 |
| Increase in Cash | 8 | -5 | 9 |
| Income (£m) | 2018 | 2017 | 2016 |
|---|---|---|---|
| Turnover | 0 | 0 | 0 |
| Cost of sales | 1 | 1 | 0 |
| Gross Profit | -1 | -0 | 0 |
| Operating Profit | -6 | -5 | -6 |
| Pre-Tax profit | -6 | -5 | -9 |
| Profit / Loss for the year | 1 | 1 | 1 |
Oncimmune Holdings Company Background
| Sector | Pharmaceuticals & Biotechnology |
|---|---|
| Activities | Oncimmune Holdings plc is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT tests for liver and ovarian cancer are in development. |
| Latest Interim Date | 13 Feb 2019 |
| Latest Fiscal Year End Date | 31 Oct 2018 |
Oncimmune Holdings Directors
| Appointed | Director | Position |
|---|---|---|
| 09 Apr 2018 | Dr Adam Mark Hill | Chief Executive Officer |
| 06 Dec 2018 | Frank Matthew Sunderland Hall | Chief Financial Officer |
| 01 Jul 2007 | Geoffrey Neil Hamilton-Fairley | Executive Vice Chairman |
| 26 Nov 2015 | Meinhard Folkert Schmidt | Non-Executive Chairman |
| 26 Nov 2015 | Timothy Brian Bunting | Non-Executive Dep Chairman |
| 26 Nov 2015 | Andrew Vaughan Unitt | Non-Executive Director |
| 26 Nov 2015 | Richard Simon Sharp | Non-Executive Director |
| 11 Oct 2016 | Carsten Schroeder | Non-Executive Director |
| 09 Jan 2018 | Dr Annalisa Mary Jenkins | Non-Executive Director |
| 23 Jun 2016 | Julian Clement Hirst | Non-Executive Director |
| 28 Sep 2018 | Dr Cheung To | Non-Executive Director |
Oncimmune Holdings Contact Details
| Company Name | Oncimmune Holdings |
|---|---|
| Company Address | Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham NG5 1PB. |
| Company Telephone | +44 (0)115 8231869 |
| Company Website | http://www.oncimmune.co.uk/ |
Oncimmune Holdings Advisors
| Auditor Name | Grant Thornton UK LLP |
|---|---|
| Auditor Address | Byron House, Cambridge Business Park, Cowley Road, Cambridge CB4 0WZ. |
| Auditor Website | http://www.grant-thornton.co.uk/ |
| Auditor Telephone | +44 (0)1223 225 600 |
| Registrar Name | Capita Registrars |
| Registrar Address | The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU. |
| Registrar Website | http://www.capitaregistrars.com/ |
| Registrar Telephone | 0870 162 3100 |
| Broker Name | Zeus Capital |
| Broker Address | 3 Ralli Courts, West Riverside, Manchester M3 5FT. |
| Broker Website | http://www.zeuscapital.co.uk/ |
| Broker Telephone | +44 (0)161 831 1512 |
| Adviser Name | Zeus Capital |
| Adviser Address | 3 Ralli Courts, West Riverside, Manchester M3 5FT. |
| Adviser Website | http://www.zeuscapital.co.uk/ |
| Adviser Telephone | +44 (0)161 831 1512 |
| Solicitor Name | Preachey & Co |
| Solicitor Address | 95 Aldwych, London, WC2B 4JF |
| Solicitor Website | http://www.peachey.co.uk/ |
| Solicitor Telephone | +44 (0)20 7316 522 |
| Stockbroker Name | n/a |
| Stockbroker Address | n/a |
| Stockbroker Website | n/a |
| Stockbroker Telephone | n/a |
